| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Interest expense | - | - | - | 2,414 |
| Total other (expense) income, net | -2,336 | 528 | 9,759 | -2,181 |
| (loss) income before provision for income taxes | -29,845 | -25,704 | 316 | -36,681 |
| Provision for income taxes | -30 | 37 | 34 | 15 |
| Net (loss) income | -29,815 | -25,741 | 282 | -36,696 |
| Net loss per share attributable to common stockholdersbasic | -0.69 | -3.47 | 0.04 | -0.18 |
| Net loss per share attributable to common stockholdersdiluted | -0.69 | -3.47 | 0.04 | -0.18 |
| Weighted average shares of common stock outstandingbasic | 43,272,773 | 7,412,990 | 6,840,035 | 200,865,276 |
| Weighted average shares of common stock outstandingdiluted | 43,272,773 | 7,412,990 | 6,869,084 | 200,865,276 |
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)